Abzyme

From Wikipedia, the free encyclopedia
Jump to: navigation, search

An abzyme (from antibody and enzyme), also called catmab (from catalytic monoclonal antibody), is a monoclonal antibody with catalytic activity. Molecules which are modified to gain new catalytic activity are called synzymes. Abzymes are usually artificial constructs, but are also found in normal humans (anti-vasoactive intestinal peptide autoantibodies) and in patients with autoimmune diseases such as systemic lupus erythematosus, where they can bind to and hydrolyze DNA. Abzymes are potential tools in biotechnology, e.g., to perform specific actions on DNA. They are also useful in hydrolysis of esters. Rate of hydrolysis was increased 100 times.

Enzymes function by lowering the activation energy of the transition state, thereby catalyzing the formation of an otherwise less-favorable molecular intermediate between reactants and products. If an antibody is developed to stabilize a molecule that's similar to an unstable intermediate of another (potentially unrelated) reaction, the developed antibody will enzymatically bind to and stabilize the intermediate state, thus catalyzing the reaction. A new and unique type of enzyme is produced.

HIV treatment[edit]

In a June 2008 issue of the journal Autoimmunity Review,[1][2] researchers S Planque, Sudhir Paul, Ph.D, and Yasuhiro Nishiyama, Ph.D of the University Of Texas Medical School at Houston announced that they have engineered an abzyme that degrades the superantigenic region of the gp120 CD4 binding site. This is the one part of the HIV virus outer coating that does not change, because it is the attachment point to T lymphocytes, the key cell in cell-mediated immunity. Once infected by HIV, patients produce antibodies to the more changeable parts of the viral coat. The antibodies are ineffective because of the virus' ability to change their coats rapidly. Because this protein gp120 is necessary for HIV to attach, it does not change across different strains and is a point of vulnerability across the entire range of the HIV variant population.

The abzyme does more than bind to the site, it actually destroys the site, rendering HIV inert, and then can attach to other viruses. A single abzyme can destroy thousands of HIV viruses. Human clinical trials will be the next step in producing treatment and perhaps even preventative vaccines and microbicides.

References[edit]

  1. ^ Planque, S; Nishiyama, Y; Taguchi, H; Salas, M; Hanson, C; Paul, S (2008). "Catalytic antibodies to HIV: Physiological role and potential clinical utility". Autoimmunity Reviews 7 (6): 473–9. doi:10.1016/j.autrev.2008.04.002. PMC 2527403. PMID 18558365.  edit
  2. ^ "UT pathologists believe they have pinpointed Achilles heel of HIV". physorg.com. Retrieved 2008-07-16.